Charles River Laboratories International Aktie
| 163,54USD | -2,11USD | -1,27% |
WKN: 939391 / ISIN: US1598641074
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 98,92 |
| The Vanguard Group, Inc. | 11,69 |
| Vanguard Group, Inc. (Subfiler) | 11,48 |
| Wellington Management Co. LLP | 7,32 |
| Wellington Management Co. LLP (Wellington Breakout) | 6,56 |
| State Street Corp. | 4,17 |
| Vanguard Health Care Fund | 3,91 |
| Kayne Anderson Rudnick Investment Management LLC | 3,79 |
| BlackRock Fund Advisors | 3,46 |
| Allspring Global Investments LLC | 3,42 |
| Vanguard Total Stock Market ETF | 3,17 |
| Allspring Special Mid Cap Value Fund | 2,88 |
| Vanguard 500 Index Fund | 2,71 |
| Vanguard Small Cap Index Fund | 2,55 |
| BlackRock Institutional Trust Co. NA | 2,42 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 17 100 | 18 400 | 20 000 | 21 400 | 21 800 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,15 | 0,16 | 0,18 | 0,19 | 0,19 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1 021 | 1 201 | 1 274 | 1 439 | 1 609 |
| Summe Anlagevermögen | 3 671 | 4 290 | 5 750 | 6 164 | 6 586 |
| Summe Aktiva | 4 693 | 5 491 | 7 024 | 7 603 | 8 195 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 3 026 | 3 347 | 4 432 | 4 579 | 4 536 |
| Summe Eigenkapital | 1 666 | 2 144 | 2 592 | 3 024 | 3 659 |
| Summe Passiva | 4 693 | 5 491 | 7 024 | 7 603 | 8 195 |
Adresse
| 251 Ballardvale Street, 01887 Wilmington | |
| Telefon | +1 (781) 222-6000 |
| Internet | http://www.criver.com |
Management
|
Barbara J. Patterson
Senior VP-Regulatory Affairs & Compliance |
|
Birgit Girshick
Chief Operating Officer & Executive Vice President |
|
Brian Bathgate
Senior Vice President-European Safety Assessment |
|
Colin Dunn
Senior VP, GM-Research Models & Services |
|
Craig B. Thompson
Independent Director |
|
Deborah Turner Kochevar
Independent Director |
|
Flavia H. Pease
Chief Financial Officer & Executive Vice President |
|
Foster T. Jordan
Senior Vice President-Microbial Solutions |
|
George E. Massaro
Lead Independent Director |
|
George Llado
Independent Director |
|
Gina M. Mullane
Chief Marketing Officer & Senior Vice President |
|
James C. Foster
Chairman, President & Chief Executive Officer |
|
John C. Ho
Chief Strategy Officer & SVP-Corporate Strategy |
|
Joseph W. LaPlume
Executive VP-Corporate Development & Strategy |
|
Julie Frearson
Chief Scientific Officer & Senior Vice President |
|
Kristen M. Eisenhauer
Chief Commercial Officer & Senior Vice President |
|
Mark Mintz
Chief Information Officer & Senior Vice President |
|
Martin W. MacKay
Director |
|
Matthew L. Daniel
Secretary, Chief Compliance Officer & Senior VP |
|
Michael Gunnar Knell
Chief Accounting Officer & Senior Vice President |
|
Nancy C. Andrews
Independent Director |
|
Reshema Kemps-Polanco
Independent Director |
|
Richard F. Wallman
Independent Director |
|
Robert J. Bertolini
Independent Director |
|
Shannon M. Parisotto
Senior VP-Global Operations & Controller |
|
Todd Spencer
Vice President-Investor Relations |
|
Victoria L. Creamer
Chief People Officer & Executive Vice President |
|
Virginia M. Wilson
Independent Director |
|
William D. Barbo
Executive Vice President |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
